| 91.69 -9.54 (-9.42%) | 06-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 125.34  |
1-year : | 137.48 |
| Resists | First : | 107.31 |
Second : | 117.7 |
| Pivot price | 100.5 |
|||
| Supports | First : | 90.48 |
Second : | 75.28 |
| MAs | MA(5) : | 97.87 |
MA(20) : | 101.94 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 1.8 |
Signal : | 4 |
| %K %D | K(14,3) : | 18.5 |
D(3) : | 21.6 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 117.7 | Low : | 35.09 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MANE ] has closed below the lower bollinger band by 19.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 101.94 - 102.44 | 102.44 - 102.93 |
| Low: | 89.16 - 89.73 | 89.73 - 90.28 |
| Close: | 90.63 - 91.54 | 91.54 - 92.43 |
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.
Thu, 28 May 2026
Veradermics to Present at Upcoming June Investor Conferences - Business Wire
Sun, 10 May 2026
Citi Remains Bullish on Veradermics, Incorporated (MANE) - Yahoo Finance
Thu, 30 Apr 2026
Veradermics (MANE) Reports Positive Phase 2/3 Results for Male Pattern Hair Loss Treatment VDPHL01 - Yahoo Finance
Tue, 28 Apr 2026
Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline Thesis (NYSE:MANE) - Seeking Alpha
Mon, 27 Apr 2026
Veradermics Shares Jump 17% on Promising Hair Loss Trial Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 42 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 79 (%) |
| Shares Short | 2,050 (K) |
| Shares Short P.Month | 1,790 (K) |
| EPS | -2.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -163.87 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -79 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -34.74 |
| PEG Ratio | 0 |
| Price to Book value | -0.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -48.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|